letrozole has been researched along with Cancer of Liver in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 9.27 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ( Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS, 2018) |
| "CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules investigated in this setting." | 8.12 | Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. ( Farhat, F; Gharib, KE; Karak, FE; Kattan, J; Macaron, W; Salloum, MA; Smith, M, 2022) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 7.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "Letrozole was then given at a daily dose of 2." | 5.31 | Endometrial stromal sarcoma: objective response to letrozole. ( Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J, 2001) |
| "The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 5.27 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ( Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS, 2018) |
| "CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules investigated in this setting." | 4.12 | Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. ( Farhat, F; Gharib, KE; Karak, FE; Kattan, J; Macaron, W; Salloum, MA; Smith, M, 2022) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 3.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "Liver resection in patients with breast cancer liver metastasis proved to be cost-effective when compared with systemic therapy alone, particularly in estrogen receptor-positive tumors or when newer agents were used." | 1.46 | Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. ( Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A, 2017) |
| "Letrozole was then given at a daily dose of 2." | 1.31 | Endometrial stromal sarcoma: objective response to letrozole. ( Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gharib, KE | 1 |
| Macaron, W | 1 |
| Kattan, J | 1 |
| Salloum, MA | 1 |
| Farhat, F | 1 |
| Smith, M | 1 |
| Karak, FE | 1 |
| Hortobagyi, GN | 1 |
| Stemmer, SM | 1 |
| Burris, HA | 1 |
| Yap, YS | 1 |
| Sonke, GS | 1 |
| Paluch-Shimon, S | 1 |
| Campone, M | 1 |
| Petrakova, K | 1 |
| Blackwell, KL | 1 |
| Winer, EP | 1 |
| Janni, W | 1 |
| Verma, S | 1 |
| Conte, P | 1 |
| Arteaga, CL | 1 |
| Cameron, DA | 1 |
| Mondal, S | 1 |
| Su, F | 1 |
| Miller, M | 1 |
| Elmeliegy, M | 1 |
| Germa, C | 1 |
| O'Shaughnessy, J | 1 |
| Selvakumar, D | 1 |
| Dube, M | 1 |
| Matey, P | 1 |
| Yazigi, R | 1 |
| RodrÃguez, T | 1 |
| Buckel, E | 1 |
| Wash, A | 1 |
| Spolverato, G | 1 |
| Vitale, A | 1 |
| Bagante, F | 1 |
| Connolly, R | 1 |
| Pawlik, TM | 1 |
| Kiyoto, S | 1 |
| Hara, F | 1 |
| Osumi, S | 1 |
| Takabatake, D | 1 |
| Takashima, S | 2 |
| Aogi, K | 1 |
| Shibaki, T | 1 |
| Morimoto, N | 1 |
| Ichinose, Y | 1 |
| Kobayashi, T | 1 |
| Fujimoto, A | 1 |
| Uchida, S | 1 |
| Sasaoki, T | 1 |
| Goto, K | 1 |
| Hata, K | 1 |
| Hirai, I | 1 |
| Tanaka, T | 1 |
| Tanino, H | 1 |
| Maluf, FC | 1 |
| Sabbatini, P | 1 |
| Schwartz, L | 1 |
| Xia, J | 1 |
| Aghajanian, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease[NCT01958021] | Phase 3 | 668 participants (Actual) | Interventional | 2013-12-17 | Completed | ||
| Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.[NCT05163106] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| Phase II, Multicenter, Single Arm Trial to Assess the Feasibility of First Line Ribociclib in Combination With a Non Steroidal Aromatase Inhibitor in Elderly Patients With Hormone Receptor Positive/HER2 Negative Advanced Breast Cancer[NCT03944434] | Phase 2 | 116 participants (Actual) | Interventional | 2018-12-27 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. (NCT01958021)
Timeframe: Up to approximately 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| LEE011 + Letrozole | 40.7 |
| Placebo + Letrozole | 27.5 |
PFS, defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1 (NCT01958021)
Timeframe: Up to approximately 20 months
| Intervention | months (Median) |
|---|---|
| LEE011 + Letrozole | NA |
| Placebo + Letrozole | 14.7 |
1 trial available for letrozole and Cancer of Liver
| Article | Year |
|---|---|
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
9 other studies available for letrozole and Cancer of Liver
| Article | Year |
|---|---|
Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Liver N | 2022 |
Surgical resection of a liver metastasis from breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Liver Neoplasms; Lymph Node | 2015 |
Ovarian granulosa cell tumour and letrozole: A case report.
Topics: Antineoplastic Agents; Fatal Outcome; Female; Granulosa Cell Tumor; Humans; Letrozole; Liver Neoplas | 2016 |
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2017 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2009 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino | 2010 |
[A case of liver metastasis of breast cancer responding to letrozole].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; | 2012 |
Endometrial stromal sarcoma: objective response to letrozole.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Liver | 2001 |